Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 24.56% is 84% above its 5-year average of 13.34%, near the high end of its 5-year range (-81.34%–24.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 72.68% above its 12-month average of 14.22%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 24.56%.
RETURN ON EQUITY (ROE)
24.56%
RETURN ON EQUITY (ROE) AVG TTM
14.22%
RETURN ON EQUITY (ROE) AVG 3Y
11.24%
RETURN ON EQUITY (ROE) AVG 5Y
13.34%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+72.68%
CURRENT VS 3Y AVG
+118.50%
CURRENT VS 5Y AVG
+84.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+158.46%
vs the sector median at left
Sotera Health Company
Market Cap
$5.20B
Return on Equity (ROE)
24.56%
TTM Avg
14.22%
3Y Avg
11.24%
5Y Avg
13.34%
Market Cap
$5.21B
Return on Equity (ROE)
-177.24%
TTM Avg
-283.26%
3Y Avg
-317.97%
5Y Avg
-235.28%
Market Cap
$5.21B
Return on Equity (ROE)
-25.83%
TTM Avg
-24.61%
3Y Avg
-23.01%
5Y Avg
-16.21%
Market Cap
$5.20B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.19B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
Market Cap
$5.32B
Return on Equity (ROE)
N/A
TTM Avg
-149.71%
3Y Avg
-15.45%
5Y Avg
-6097.55%
Market Cap
$5.09B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$5.07B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$5.06B
Return on Equity (ROE)
3.38%
TTM Avg
1.14%
3Y Avg
-0.67%
5Y Avg
-0.98%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sotera Health Company (SHC) | $5.20B | 24.56% | 14.22% | 11.24% | 13.34% |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.21B | -177.24% | -283.26% | -317.97% | -235.28% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | -25.83% | -24.61% | -23.01% | -16.21% |
| Doximity, Inc. (DOCS)vs › | $5.20B | 18.24% | 20.62% | 17.32% | 27.02% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.19B | -70.85% | -75.76% | -70.25% | -57.77% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | -149.71% | -15.45% | -6097.55% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.09B | -161.00% | -110.38% | -86.51% | -75.97% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 8.67% | 8.42% | 7.80% | 5.80% |
| Waystar Holding Corp. (WAY)vs › | $5.06B | 3.38% | 1.14% | -0.67% | -0.98% |
| Erasca, Inc. (ERAS)vs › | $4.96B | -79.37% | -38.23% | -43.73% | -49.41% |
ROE
24.6%
ROA
4.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 24.56% |
| 2026-03-31 | 18.92% |
| 2025-12-31 | 12.86% |
| 2025-09-30 | 10.07% |
| 2025-06-30 | 4.70% |
| 2025-03-31 | 5.99% |
| 2024-12-31 | 10.96% |
| 2024-09-30 | 15.05% |
| 2024-06-30 | 9.48% |
| 2024-03-31 | 12.78% |
| 2023-12-31 | 11.58% |
| 2023-09-30 | -81.34% |
| 2023-06-30 | -64.12% |
| 2023-03-31 | -72.38% |
| 2022-12-31 | -66.69% |
| 2022-09-30 | 20.13% |
| 2022-06-30 | 19.58% |
| 2022-03-31 | 21.29% |
| 2021-12-31 | 19.94% |
| 2021-09-30 | 7.08% |
| 2021-06-30 | 1.87% |
| 2021-03-31 | -5.57% |
| 2020-12-31 | -8.54% |
